Gale.cengage.co.uk
Graham & Whiteside
Australia • Brazil • Japan • Korea • Mexico • Singapore • Spain • United Kingdom • United States
Major Pharmaceutical and Biotechnology Companies of the World 2009
Africa (South of the Sahara)
Malaysia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
Angola . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Mongolia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
Benin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Myanmar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Botswana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Nepal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Burkina Faso . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
New Zealand . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Cape Verde . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
North Korea . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Ethiopia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Pakistan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Gabon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
Papua New Guinea . . . . . . . . . . . . . . . . . . . . . 138
Ghana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
People’s Republic of China . . . . . . . . . . . . . . . 138
Ivory Coast . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Philippines . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
Kenya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Singapore . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Lesotho . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
South Korea . . . . . . . . . . . . . . . . . . . . . . . . . . . 166Sri Lanka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
Madagascar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Taiwan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
Malawi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Thailand . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178
Mali . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Vietnam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180
Mauritius . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4Mozambique . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Eastern Europe and the Commonwealth of Indepen-
Niger . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
dent States
Nigeria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Armenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
Senegal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Belarus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
Seychelles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Bosnia and Herzegovina . . . . . . . . . . . . . . . . . 183
South Africa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Croatia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
Swaziland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Georgia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
Togo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Kazakhstan . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
Uganda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Macedonia . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
Zambia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Montenegro . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
Zimbabwe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Russia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
Arab World
Serbia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189Ukraine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
Algeria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Uzbekistan . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
Bahrain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16Egypt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Gaza and West Bank . . . . . . . . . . . . . . . . . . . . . 22
Austria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
Iraq . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Belgium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
Jordan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Bulgaria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
Kuwait . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Cyprus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
Lebanon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Czech Republic . . . . . . . . . . . . . . . . . . . . . . . . 205
Libyan Arab Jamahiriya . . . . . . . . . . . . . . . . . . . 30
Denmark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
Mauritania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Estonia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216
Morocco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Finland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217
Oman . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
Qatar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249
Saudi Arabia . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Greece . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275
Sudan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Hungary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279
Syrian Arab Republic . . . . . . . . . . . . . . . . . . . . . 42
Iceland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284
Tunisia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Israel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285
United Arab Emirates . . . . . . . . . . . . . . . . . . . . 44
Italy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291
UAE (Abu Dhabi) . . . . . . . . . . . . . . . . . . . . . . . . 44
Latvia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301
UAE (Dubai) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Liechtenstein . . . . . . . . . . . . . . . . . . . . . . . . . . 302
UAE (Fujairah) . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Lithuania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302
UAE (Ras Al Khaimah) . . . . . . . . . . . . . . . . . . . . 46
Luxembourg . . . . . . . . . . . . . . . . . . . . . . . . . . 303
UAE (Sharjah) . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Malta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303
Yemen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Monaco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303Netherlands . . . . . . . . . . . . . . . . . . . . . . . . . . . 304
Asia and Australasia
Norway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311
Australia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Poland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314
Bangladesh . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Portugal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322
Hong Kong SAR . . . . . . . . . . . . . . . . . . . . . . . . . 58
Republic of Ireland . . . . . . . . . . . . . . . . . . . . . 327
India . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Romania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331
Indonesia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
Slovakia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333
Iran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Slovenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334
Japan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
Spain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336
Sweden . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 352
Chile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 416
Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . . 359
Colombia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 418
Turkey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 374
Costa Rica . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420
UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 376
Ecuador . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 421El Salvador . . . . . . . . . . . . . . . . . . . . . . . . . . . 422
Latin America
Guatemala . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422
Argentina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399
Guyana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422
Belize . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402
Honduras . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422
Bolivia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402
Mexico . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422
Brazil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402
Nicaragua . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
CARIBBEAN - Antigua and Barbuda . . . . . . . . 412
Panama . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
CARIBBEAN - Aruba . . . . . . . . . . . . . . . . . . . . 412
Paraguay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
CARIBBEAN - Bahamas . . . . . . . . . . . . . . . . . 412
Peru . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
CARIBBEAN - Barbados . . . . . . . . . . . . . . . . . 413
Suriname . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431
CARIBBEAN - Bermuda . . . . . . . . . . . . . . . . . . 413
Uruguay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431
CARIBBEAN - Cayman Islands . . . . . . . . . . . . 413
Venezuela . . . . . . . . . . . . . . . . . . . . . . . . . . . . 432
CARIBBEAN - Dominican Republic . . . . . . . . . 413CARIBBEAN - Grenada . . . . . . . . . . . . . . . . . . 414
North America
CARIBBEAN - Jamaica . . . . . . . . . . . . . . . . . . 414
Canada . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434
CARIBBEAN - Netherlands Antilles . . . . . . . . . 415
USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 440
CARIBBEAN - Puerto Rico . . . . . . . . . . . . . . . . 415CARIBBEAN - St Lucia . . . . . . . . . . . . . . . . . . 415
CARIBBEAN - St Vincent and the Grenadines . 416
Alphabetical Index . . . . . . . . . . . . . . . . . . . . . 471
CARIBBEAN - Trinidad and Tobago . . . . . . . . . 416
Index by Country . . . . . . . . . . . . . . . . . . . . . . 495
WAKO PURE CHEMICALS INDUSTRIES . . . 00953
Rhythm, Kikuron, Kolberon, Tocks, Aoi Umi, Hakubiso, Mori
TORII PHARMACEUTICAL CO LTD
VITAL-NET INC
Branch Offices: Tokyo; New York, USA; London, UK
Address: 3-4-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-
Former name: Sun-S Inc
Subsidiary Companies: (100% owned unless stated):
Address: 1-1 Ohtemachi, Aoba-ku, Sendai 980-8581
HOKURIKU MEDICAL SERVICE CO LTD; Taiyo Sangyo Co
Ltd; Tomix Co Ltd; TOYAMA EUROPE LTD (UK); Toyama
Kouei Co Ltd; TOYAMA USA Inc (USA); White Public Rela-
Board of Directors: Norihiko Matsuo (President), Hiroshi Imai
Board of Directors: Jun Suzuki (Chairman), Ken Suzuki (Rep-
(Managing Director/Chief Pharmaceutical Marketing), Yuji
Kagohashi (Director/Chief of R&D & Production), Hiroshi
PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals
Kanaya (Executive Deputy President/Chief of Corporate
Planning & Admin), Masanori Wada (Director/QA)
Senior Executives: Tadashi Kadota (Corporate Auditor),
Financial Information: 2008: Consolidated
Yoshiaki Otsuka (Corporate Auditor), Yoshiyuki Taniguchi
Principal Shareholders: Hikoji Suzuki (6.7%); Suzuhiko Ltd
(Corporate Auditor), Hideo Yamaguchi (Corporate Auditor)
Sales turnover
PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals
Parent Company: Japan Tobacco Inc, Japan (00864)
Financial Information: Consolidated figures
Sales turnover
Principal Shareholders: Japan Tobacco Inc (53.5%)
TRANS GENIC INC
Address: 3-14-3 Minami-Kumamoto, Kumamoto-shi, Ku-
Sales turnover
WAKAMOTO PHARMACEUTICAL CO LTD
Board of Directors: Satoru Endo (Auditor), Toshio Kajima
Address: 1-5-3 Nihonbashi-Muromachi, Chuo-ku, Tokyo
(Auditor), Masahiro Koreishi (President and Chief Execu-
tive Officer), Yasuhiko Matsuo (Internal Auditor), Michita
Satoh (Director), Jun Tanaka (Executive Director), Ken-ichi
Website: www.wakamoto-pharm.co.jpBoard of Directors: Kiyoaki Makita (Chairman), Takashi Ishii
PRINCIPAL ACTIVITIES: Analysis of genes and genetics infor-
TOWA PHARMACEUTICAL CO LTD
Principal Banks: Shoko Chukin Bank; The Bank of Tokyo-
PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals
Address: 2-11 Shinbashi-cho, Kadoma 571-8580, Osaka
Principal Shareholders: Kissei Pharmaceutical (9.5%); Brast-
Board of Directors: Itsuro Yoshida (President)
PRINCIPAL ACTIVITIES: Manufacture of drugs for respiratory
Financial Information: Consolidated figures
Branch Offices: Osaka; Hannan; Nagoya; Takarazuka;
Sales turnover
Sales turnover
Principal Shareholders: Yoshida Jimsho (17.4%); Yoshida
Kosan (11.6%); Yoshida Kikaku (8.8%); Itsuro Yoshida
Date of Establishment: April 1957No of Employees: 1,125 (group)Financial Information: Consolidated figures
TSUMURA & CO
WAKO PURE CHEMICALS INDUSTRIES LTD
Sales turnover
Address: 2-17-11 Akasaka, Minato-ku, Tokyo 107-8521
Address: 3-1-2 Doshomachi, Chuo-ku, Osaka 540-8605
Board of Directors: Junichi Yoshii (President)
PRINCIPAL ACTIVITIES: Manufacture and sale of pharmaceu-
Board of Directors: Hajime Ikezoe (President), Syunrou Kawa-
ticals, quasi-pharmaceuticals and toiletries
mura (Senior Managing Executive Officer), Eisuke Kimura
Branch Offices: Sapporo; Sendai; Tokyo; Nagoya; Osaka;
(Managing Executive Officer/GM Corporate Production/QA),
Yokohama; Shizuoka; Kyoto; Kobe; Takamatsu; Tachikawa;
Takeo Matsumoto (Managing Executive Officer/GM Corpo-
rate Admin & Personnel), Norimichi Ueno (Senior Managing
TOYAMA CHEMICAL CO LTD
Executive Officer), Yoshiharu Watabiki (Senior Managing
Address: 3-2-5 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023
Senior Executives: Shigeru Fukushima (Corporate Auditor),
Principal Shareholders: Japan Trustee Services Bank
Eio Okayama (Corporate Auditor), Toyoji Yoshida (Corporate
(12.6%); Master Trust Bank of Japan (5.7%)
PRINCIPAL ACTIVITIES: Provision of laboratory chemicals,
Board of Directors: Katsuhiko Nakano (Chairman), Masuji
specialty chemicals and diagnostic reagents for genetic
Sugata (President), Shinichiro Inushima (Director), Shozo
Financial Information: Consolidated figures
engineering research, tissue culture, measurement of
Kakimoto (Director), Yoshiharu Murotani (Director), Akira
environmental pollutants, immunological research, chro-
Ohira (Director), Hideo Sanada (Director/Senior Executive
matography, organic syntheses and biochemical research
Officer), Yukio Yanagida (Director), Hiroichi Yoshida (Direc-
Sales turnover
Subsidiary Companies: (100% owned unless stated): Wako
Chemicals GmbH (Germany); Wako Chemicals USA Inc
PRINCIPAL ACTIVITIES: Manufacture and sale of pharmaceu-
ticals, antibiotics and industrial chemicals
Trade Names: Ozex, Tomiron, Pentcillin, Tazocin, Cefoper-
azin, Tomiporan, Luprac, Flucam, Baxo, Abovis, Pirocut,
03192
SIGMA PHARMACEUTICAL PLC
Indurgan, Lodine SR(TM), Mecloderm, Mecloderm F, Mep-
Principal Law Firm: Fasken Martineau Stringer Saul LLP;
tid(TM), Midon, Monocid*, PACIS(R), PENTASA(R), PROA-
Board of Directors: Gerald Corbett (Chairman), Garry Watts
MATINE(R), Reminyl(TM), Rentibloc(R), Rentylin(R), SECOND
(Chief Executive Officer), Richard Adam (Non-Executive
LOOK, Sertagyn, Testimonia, Trandate, Trizivir(R), VERA-
Director), Ian Adamson (Managing Director, Europe and
Americas), Peter Johnson (Non-Executive Director), Mark
Subsidiary Companies: (100% owned unless stated): Shire
Moran (Finance Director), Peter Read (Non-Executive Direc-
BioChem, Inc (Canada); Shire Deutschlaand GmbH & Co KG
Principal Shareholders: HBM BioVentures (Cayman) Ltd
(Germany); Shire France SA (France); Shire Human Generic
Management: Maria Buxton-Smith (Company Secretary),
Therapies (USA); Shire Italia SpA (Italy); Shire Pharma-
Paul Doherty (Head of Corporate Affairs), Jan Young (Head
ceutical Contracts Ltd (Singapore); Shire Pharmaceuticals
Financial Information: Consolidated figures
Group Ltd; Shire Pharmaceuticals Iberica SL (Spain); Shire
PRINCIPAL ACTIVITIES: Manufacture and distribution of
Pharmaceuticals Ireland Ltd (Republic of Ireland); Shire US
healthcare products, barrier contraceptives, footwear and
Manufacturing Inc (USA); Shire, Inc (USA)
Sales turnover
Mergers and Acquisitions: In Novebember 2007 the Group
acquired the business and certain assets of Vasyli Australia
Pty Ltd, Vasyli (NZ) Ltd, and Vasyli UK Ltd.
Major Products: Scholl footcare and footware, Durex con-
Principal Shareholders: Legal & General Group plc (5.26%)
doms, Regent Biogel surgical gloves, Marigold household
and industrial gloves, OTC products including Syndol,
Financial Information: 2006: Consolidated Figures; GAAP.
Cuprofen, Resolve, Ralgex, Tubigrip and wound manage-
SOURCE BIOSCIENCE PLC
Former name: Medical Solutions plc
Trade Names: Adapta, Avanti, Cuprofen, Derbac, Diana, Dio-
Address: 1 Orchard Place, Nottingham Business Park, Not-
calm, Dr Scholl, Due In Uno, Durex, Durex Sensation, Eu-
lactol, Fresh Step, Full Marks, Gelactiv, Hydra-Gel, Meltus,
Mister Baby, Natruclear, Paramol, Party Feet, Performa,
Pescura, Play, Pleasuremax, ProSport, Ralgex, Remegel,
Resolve, Sauber, Scholl, Scholl Flight Socks, Syndol, Wood-
Board of Directors: Laurie Turnbull (Chairman), Dr Nick Ash
Subsidiary Companies: (100% owned unless stated): LIG
(Managing Director), Dr Sue Foden (Non-Executive Direc-
China BV (Netherlands); London International GmbH (Ger-
tor), Dr Nick Leaves (Operations Director), Robin Slinger
many); London International Group Ltd; London International
(Non-Executive Director), Dr Thomas Weaver (Commercial
Norway A/S (Norway); LRC North America Inc (USA); LRC
Products Ltd; LRC Products Ticaret ve Pazarlama Ltd Sirketi
PRINCIPAL ACTIVITIES: The Group is a holding company
(Turkey); New Bridge Holdings BV (Netherlands); NV SSSL
SIGMA PHARMACEUTICAL PLC
and the principal activities of the subsidiaries are the mar-
Healthcare Belgium SA (Belgium); Qingdao London Durex
Address: 1 Colonial Way, Imperial Way, Watford WD2 4LA
keting and sale of microscopy hardware and software
Company Limited (People’s Republic of China); Scholl Con-
and image analysis and management systems, develop-
sumer Products Ltd; Scholl (Investments) Ltd; Scholl Ltd;
ment of intellectual property in cancer diagnosis/prognosis
Scholl (UK) Ltd; Seton Schol Ireland Holdings (Republic of
systems and the development, support and assembly of
Ireland); Seton Scholl European Holdings BV (Netherlands);
diagnostic telepathology workstations and the supply of a
Seton Scholl International Ireland (Republic of Ireland);
Board of Directors: B K H Shah (Chairman and Managing
range of chemicals, consumables, provision of specialist
Simco Ltd; Sonet Investments Ltd; Sonet Prebbles Ltd;
pathology services, laboratory instruments and software
Sonet Scholl Overseas Investments Ltd; Sonet Scholl UK
Management: Mrs D K Shah (Manager), Mrs K Shah (Secre-
for histopathology laboratories. Manufacture and supply of
Ltd; SSL Americas Inc (USA); SSL Australia Pty Ltd (Aus-
tary), M H Shah (Finance Director), Mrs J Shah (Manager)
infection and contamination control products to the hospital
tralia); SSL Canada Inc (Canada); SSL Czeska Republika
Senior Executives: K H Shah (Company Secretary)
and pharmaceutical industry and dermatology
sro (Czech Republic); SSL Healthare Italia SpA (Italy); SSL
PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals
Mergers and Acquisitions: In April 2007 Source BioScience
Healthcare Brands SA (Spain); SSL Healthcare Danmark
Principal Banks: National Westminster Bank plc
plc acquired 40% of the ordinary share capital of the private
A/S (Denmark); SSL Healthcare Deutschland GmbH & Co
healthcare provider Number One Health Group Limited. In
KG (Germany); SSL Healthcare France SA (France); SSL
July 2007 Source BioScience plc completed the acquisition
Healthcare GmbH (Germany); SSL Healthcare (Hong Kong)
of the entire ordinary share capital of Geneservice Limited.
Ltd (Hong Kong SAR); SSL Healthcare Hong Kong Ltd (Hong
Subsidiary Companies: (100% owned unless stated): Fair-
Kong SAR); SSL Healthcare Ireland Ltd (Republic of Ire-
field Imaging Ltd; Fairfield Telepathology Ltd; Geneservice
land); SSL Healthcare Japan Ltd (Japan); SSL Healthcare
Ltd (75%); Kinetic Imaging Ltd; Medical Solutions FZ LLC
SKYEPHARMA PLC
Nederland BV (Netherlands); SSL Healthcare (Norge) A/S
(United Arab Emirates); Medical Solutions (London) Ltd
(Norway); SSL Healthcare Oesterreich GmbH (Austria);
(75%); Medical Solutions (Nottingham) Ltd (75%); Pathlore
SSL Healthcare (Polska) Sp zoo (Poland); SSL Healthcare
Ltd; Second Opinion Solutions AS (75.3%) (Norway)
Singapore Pte Ltd (Singapore); SSL Healthcare Suisse SA
Associated Companies: Number One Health Group Ltd (40%)
(Switzerland); SSL Healthcare Thailand Ltd (Thailand); SSL
Principal Banks: The Royal Bank of Scotland plc
Hellas SA (Greece); SSL Holdings Inc (USA); SSL Mag-
yarorszag Kft (Hungary); SSL Manufacturing (Thailand)
Board of Directors: Jeremy Scudamore (Chairman), Frank
Ltd (Thailand); SSL New Zealand Ltd (New Zealand); SSL
Condella (Chief Executive Officer), Alan Bray (Non-Executive
Products Ltd; SSL Romania SRL (Romania); SSL Slovnsko
Director), Dr Ken Cunningham (Chief Operating Officer), Pe-
spol sro (Slovakia); SSL Sverige AB (Sweden); SSL-TTK Ltd
ter Grant (Finance Director), Stephen Harris (Non-Executive
(51%) (India); TTK-LIG Ltd (49.87%) (India); Tubifoam Ltd
Director), Dr Argeris Karabelas (Non-Executive Director),
Principal Shareholders: Aberforth Partners (15.68%); Mr
John Murphy (Company Secretary), Jean-Charles Tschudin
S Varkey (8.65%); Mr J Mellon (5.72%); Texas Holdings
PRINCIPAL ACTIVITIES: Research, development, manufacture
Principal Law Firm: Allen & Overy; Hammonds
Financial Information: Consolidated figures
Divestments: In March 2007 the Group disposed of its In-
Trade Names: Paxil CR, Xatral OD, Madopar DR, Coruno,
Sales turnover
Nifedipine, Diclofenac, Dilacor XR, Requip, Statin NK-104,
Principal Shareholders: Blackrock Inc (14.94%); Liontrust
Foradil DPI, Formoterol HFA, Pulmicort HFA, Formoterol
Investment Services Ltd (5.51%); FMR Corp (5.03%)
Combi, DepoCyt, DepoMorphine, DepoBupivacaine, Psorax-
ine, Interferon alpha-2b, HGH, Solareze, Hyclinda, Acyclovir,
Financial Information: Consolidated figures
Propofol IDD-D, Busulfan, Fenofibrate, Multiple
Subsidiary Companies: (100% owned unless stated): Jago
Holding AG (Switzerland); Jagotec AG (Switzerland);
Sales turnover
Krypton Ltd (Gibraltar); SkePharma AG (Switzerland);
SkePharma Canada Inc (Canada); SkyePharma AB (Swe-
SSL INTERNATIONAL PLC
den); SkyePharma Holding AG (Switzerland); SkyePharma
Address: 35 New Bridge Street, London EC4V 6BW
Holding Inc (USA); SkyePharma (Jersey) Ltd; SkyePharma
Production SAS (France); SkyePharma US Inc (USA)
Alphabetical Index
Alphabetical
Alphabetical Index
Abbott Laboratorios Lda [Portugal ] 02605
A S Bugshan & Bros [Saudi Arabia] 00326
Index by Country
Getz Bros & Co (Singapore) Pte Ltd 01273
Said Mohamed Obaid Binzagr & Co 00352
Source: http://gale.cengage.co.uk/images/2009%20PHARMBIO%20SAMPLES.pdf
Décret n° 2000-2339 du 10 octobre 2000, fixant la liste des déchets dangereux (JORT n° 86 du 27 octobre 2000) Sur proposition de la ministre de l'environnement et de l’aménagement du territoire, Vu la loi n° 92-11 du 3 février 1992, portant ratification de la convention de "Bamako" sur l'interdiction d'importer en Afrique des déchets dangereux et sur le contrôle des mo
STUDENT'S HEALTH HISTORY (To be filled out by Parents) . Your child's health and well-being is of great importance to us. Please complete this form carefully in order to assist us support child. First Name: Middle : Last Sibling at AIS: Name & Grade: Name of Emergency Contact in Muscat (other than yourself) Telephone # STUDENT'S HEALTH HISTORY Does your child have any of the following
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z |
0-9 |